What we’re reading, November 15, 2016: retail health clinics are not associated with decreased emergency department visits; House Speaker Paul Ryan will push for Medicare reform along with repeal of the Affordable Care Act; screening of donated blood finds just a fraction of units are contaminated with the Zika virus.
The increasing popularity of retail health clinics has not lowered the amount of emergency department (ED) visits for low-acuity conditions, according to a study in the Annals of Emergency Medicine. The authors report that the major effect of retail clinics is “new use,” when people who would not otherwise have sought treatment visit these convenient retail settings for minor issues. People can generally discern whether they are having a true medical emergency and pick the most appropriate care setting, meaning that retail clinics do not directly compete with EDs.
House Speaker Paul Ryan is preparing for a repeal of the Affordable Care Act (ACA) after President-elect Donald Trump takes office, and he has recently suggested that the replacement would include Medicare reforms. In a Fox News interview, he blamed the ACA for Medicare’s financial troubles, which he said would be addressed by the Republican plan to replace the healthcare law. Trump’s transition website states his administration would “modernize Medicare,” but does not include specifics.
Many American blood banks have been testing donated blood for the Zika virus at a cost of $6 to $10 per unit, even though they are not yet legally required to. They report that screenings have found only 40 positive results out of around 800,000 blood donations tested over the last 6 months. In contrast, about 1% of blood donors in Puerto Rico were infected with Zika in July.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More